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Gender- and Race-Specific Metabolic Score and
Cardiovascular Disease Mortality in Adults:
A Structural Equation Modeling Approach—United States,
1988-2006
Carla I. Mercado1, Quanhe Yang1, Earl S. Ford2, Edward Gregg3 and Amy L. Valderrama4
Objective: Consider all metabolic syndrome (MetS) components [systolic (SBP) and diastolic (DBP) blood
pressures, waist circumference, HDL cholesterol, triglycerides (TG), and fasting glucose] and gender/race
differential risk when assessing cardiovascular disease (CVD) risk.
Methods: We estimated a gender- and race-specific continuous MetS score using structural equation
modeling and tested its association with CVD mortality using data from National Health and Nutrition
Examination Survey III linked with the National Death Index. Cox proportional hazard regression tested
the association adjusted for sociodemographic and behavior characteristics.
Results: For men, continuous MetS components associated with CVD mortality were SBP (hazard
ratio51.50, 95% confidence interval51.14-1.96), DBP (1.48, 1.16-1.90), and TG (1.15, 1.12-1.16). In
women, SBP (1.44, 1.27-1.63) and DBP (1.24, 1.02-1.51) were associated with CVD mortality. MetS score
was not significantly associated with CVD mortality in men; but significant associations were found for all
women (1.34, 1.06-1.68), non-Hispanic white women (1.29, 1.01-1.64), non-Hispanic black women (2.03,
1.12-3.69), and Mexican-American women (3.57, 2.21-5.76). Goodness-of-fit and concordance were over-
all better for models with the MetS score than MetS (yes/no).
Conclusions: When assessing CVD mortality risk, MetS score provided additional information than MetS
(yes/no).
Obesity (2015) 23, 1911-1919. doi:10.1002/oby.21171
Introduction
Cardiovascular disease (CVD) is the leading cause of death in the
US and worldwide (1). A cluster of risk factors commonly found
among individuals with CVD (dyslipidemia, hypertension, hypergly-
cemia, and excess abdominal fat) led to the development of a condi-
tion known as metabolic syndrome (MetS) (2). Most recently, a
harmonized MetS definition was presented as having abnormal
values for three of the five metabolic components: blood pressure,
fasting glucose, waist circumference, HDL cholesterol, or triglycer-
ides (3), based on established cut points.
Although MetS predicts CVD events (4,5), there are some major
limitations to the most recent harmonized definition of MetS (3).
First, the established cut points of each metabolic component may
not be most effective in predicting CVD risk for certain subgroups
or populations. One example is the MetS paradox among African-
Americans who have greater prevalence of hypertension and better
cholesterol profiles than other races/ethnicities (6,7), and cut points
may need to be adapted to identify early CVD risk. Additionally,
the current MetS definition does not distinguish between which
components are present, and there may be interaction between com-
binations of components that result in greater CVD risk than others.
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Additional limitations raised by a joint statement from the American
Diabetes Association and the European Association for the Study of
Diabetes includes ill-defined cut points with possible loss of infor-
mation, lack of basis for the inclusion or exclusion of other CVD
risk factors, and treatment of MetS is no different than the treatment
of its components (8). Overall, the medical value of diagnosing
MetS was questioned. However, CVD events and mortality have
been found to be driven by MetS independently from the compo-
nents (9). Additionally, individuals with MetS are at increased risk
of CVD mortality and all-cause mortality compared with those with-
out MetS (10-13). Even though these studies have consistently found
a positive relationship between MetS and CVD mortality, MetS is
criticized due to limitations of the definition (yes/no) and the inflex-
ibility of evaluating abnormal MetS components differently for race
and gender subgroups.
Even though the harmonized definition has provided country- and
gender-specific cut points for a couple of components, ideally we
would use the measured value of each component when assessing
CVD risk while acknowledging differential risk among certain popu-
lations. In this study, we tested independent associations between
each metabolic component and CVD mortality. Then, we used a
method that addresses the limitations of MetS by estimating an indi-
vidual continuous MetS score based on the actual value of all com-
ponents and tested its association with CVD mortality.
Methods
Study population
Data from the National Health and Nutrition Examination Survey III
(NHANES III) was used where participants were selected from a
complex, multistage, probability sampling design to represent the
non-institutionalized US population (14). NHANES III was con-
ducted from 1988 to 1994 and contains data on 19,288 nonpregnant
adults aged 18 years or older. Data on participants from NHANES
III were linked to death certificates from the National Death Index
to obtain mortality status through December 31, 2006 (15). CVD
mortality was classified as cause of death from Major Cardiovascu-
lar Diseases or ICD-10 codes of I00 to I78.
Of the 19,288 nonpregnant adults, 25 were ineligible for mortality
linkage resulting in a remaining 19,263 participants. Participants
were then excluded if there were: no fasting lab data available (n =
11,157); no measurements for blood pressure (n = 2345) or anthropo-
metric (n = 3154); medical history of cancer (n = 775), heart failure
(n = 747), stroke (n = 646), or heart attack (n = 932); or missing
covariate data (n = 772). These numbers are not mutually exclusive
and 5759 participants remained in this study. Morning sample
weights, also known as fasting weights, were used to account for
non-response due to not fasting or missing laboratory data.
Measurements
Participants underwent interviews and detailed physical exams.
Waist circumference was measured to the nearest 0.1 cm from the
top of the iliac crest with the tape measure parallel to the floor.
Blood pressure was determined based on an average of three blood
pressure measurements. Blood samples were collected to obtain
measures of plasma glucose and lipid profiles (HDL cholesterol and
triglycerides).
MetS was based on the latest harmonized definition of having three
or more abnormal values of any of the following components: blood
pressure, fasting glucose, waist circumference, HDL cholesterol, and
triglycerides (3). Presence of the blood pressure component was a
systolic blood pressure 130 mm Hg, diastolic blood pressure
85 mm Hg, or prescribed medication use for high blood pressure.
Abnormal fasting glucose was defined as 100 mg/dl or the use of
glucose altering medication (insulin/diabetic pills). Gender-specific
cut points were specified for waist circumference (men: 102 cm
and women: 88 cm) and HDL cholesterol components (men:
<40 mg/dl and women: <50 mg/dl). Abnormal triglycerides were
150 mg/dl. Participants meeting three or more of these criteria
were categorized as having MetS.
Statistical analysis
All analyses used sampling weights and adjusted variance estimates
to account for the complex sampling design. Demographic character-
istics were described as count and percent for discrete variable and
mean with standard errors for continuous variables. Structural equa-
tion modeling, a statistical estimation method, was used to calculate a
metabolic score for each participant based on the values of the fol-
lowing metabolic components: systolic blood pressure, diastolic
blood pressure, fasting glucose, waist circumference, HDL choles-
terol, and triglycerides. During the estimation process, correlated
errors were specified between systolic and diastolic blood pressure
measures as well as between HDL cholesterol and triglycerides due
to the relationship these variables have with each other. For the pur-
pose of comparing components’ contribution to the metabolic score,
factor loadings were standardized based on the variance of the fitted
model. Because gender and race/ethnic differences in the distribution
of some of these components may exist, path diagrams were esti-
mated separately for each gender-race subgroup, and differences were
tested using Score and Wald tests. Goodness-of-fit of the specified
path diagrams were assessed by the standardized root mean squared
residuals (SRMR; good fit 0.08) and by the coefficient of determi-
nation (CD; good fit >0.56 which is equivalent to an R2 of 0.75).
Cox proportional hazards regression analysis was used to test the
association between time to CVD death in five ways: (1) each con-
tinuous metabolic component independently, (2) harmonized MetS
(yes/no), (3) the number of metabolic components present based on
harmonized cut points and (4) the metabolic score calculated from
structural equation modeling. When testing the independent associa-
tion between CVD mortality and each metabolic component, compo-
nents were standardized to have a distribution of mean zero and a
standard deviation of one for the purpose of coefficient comparison
across models. Meaning, the greatest coefficient with significance
would be considered a more important predictor. Person-time used
in these analyses was the date from the NHANES in-person exam to
the day of death or December 31, 2006 for those assumed alive.
Since metabolic scores are gender and race specific, hazard ratios
were stratified by gender and race/ethnicity. Models were adjusted
for: age (years), education (highest grade or year of school com-
pleted), physical activity [active (moderated physical activity 5
times per week or vigorous physical activity 3 times per week) or
inactive], smoking status (never, former, or current), alcohol con-
sumption (none, less than three drinks per week, or three or more
per week), and self-reported medication use for hypertension, diabe-
tes, or high cholesterol. Statistical significance was denoted as P
value less than 0.05.
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Comparison between models using the harmonized MetS definition,
number of abnormal components, and metabolic score were based
on predictability of the models from concordance analysis (Harrell’s
C coefficient and Gonen and Heller’s K coefficient) and goodness-
of-fit (Akaike Information Criterion, Bayesian Information Criterion,
and Royston’s R2). These models were also tested against a model
having all the MetS components in the model as continuous varia-
bles. All analyses were performed using STATA 13.0 (StataCorp
LP, College Station, TX).
Results
Demographic, anthropometric, and laboratory characteristic by gen-
der and race/ethnicity are presented in Table 1. Women had an older
age distribution than men with 15% being 65 years or older compared
with 11% of men. Mexican-Americans were a younger group with
76% between the ages of 18 and 44 years compared with African-
Americans (69%) and non-Hispanic whites (57%). About 47% of
men and 43% of women had some college education or college
degree. Education varied between race/ethnic groups with 18% of
Mexican-Americans, 34% of African-Americans, and 48% of non-
Hispanic whites with some college education or college degree attain-
ment. The prevalence of MetS did not greatly vary by gender, but
there was some variability among race/ethnic groups with 22% of
non-Hispanic blacks meeting harmonized MetS compared with 28%
non-Hispanic whites and 31% of Mexican-Americans. Person-time of
follow-up was similar between gender and race/ethnic groups.
Systolic blood pressure, diastolic blood pressure and triglycerides
were independently associated with CVD mortality in non-Hispanic
white men (Table 2). In these associations, the strength of association
was greatest for systolic blood pressure (adjusted standardized hazard
ratio5 1.51, 95% confidence interval: 1.06-2.16) and diastolic blood
pressure (1.51, 1.10-2.07) compared with triglycerides (1.16, 1.13-
1.19). Among non-Hispanic black men, systolic (1.58, 1.17-2.13) and
diastolic (1.53, 1.21-1.93) blood pressures as well as HDL choles-
terol (1.43, 1.14-1.79) were independently associated with CVD mor-
tality. None of the metabolic components were independently associ-
ated with CVD mortality among Mexican-American men.
Systolic blood pressure was associated with CVD mortality within
all race/ethnic groups in women and the strongest association was
observed among Mexican-American (1.97, 1.20-3.23) compared
with non-Hispanic whites (1.43, 1.22-1.68) and non-Hispanic blacks
(1.44, 1.18-1.75) (Table 2, unadjusted estimates Supporting Informa-
tion Table S1). Diastolic blood pressure was associated with CVD
mortality among all women (1.24, 1.02-1.51). Other significant inde-
pendent association with CVD mortality was fasting glucose (1.68,
1.40-2.01) in Mexican-American women.
There was slight variation in the standardized factor loadings from
the structural equation modeling by gender and race/ethnicity (Fig-
ure 1). Based on the Score and Wald tests (Supporting Information
Table S2), factor loadings in the path diagrams were significantly
different across gender and race groups. Overall, the standardized
factor loadings were greatest for waist circumference (ranging from
0.58 to 0.81) for all subgroups. In men, standardized factor loading
absolute values for all other metabolic components were close to
half that of waist circumference, with HDL having a negative value.TA
B
LE
1.
(c
o
n
ti
n
u
e
d
).
Al
l,
m
ea
n
(S
E)
M
en
,
m
ea
n
(S
E)
W
om
en
,
m
ea
n
(S
E)
N
on
-H
is
pa
ni
c
W
hi
te
,
m
ea
n
(S
E)
N
on
-H
is
pa
ni
c
Bl
ac
k,
m
ea
n
(S
E)
M
ex
ic
an
-A
m
er
ic
an
,
m
ea
n
(S
E)
W
ai
st
ci
rc
um
fe
re
nc
e
(c
m
)
91
.3
(0
.3
)
95
.1
(0
.4
)
87
.7
(0
.5
)
91
.1
(0
.4
)
92
.1
(0
.4
)
92
.2
(0
.5
)
Sy
st
ol
ic
bl
oo
d
pr
es
su
re
(m
m
H
g)
12
0.
9
(0
.4
)
12
3.
8
(0
.5
)
11
8.
2
(0
.6
)
12
0.
8
(0
.5
)
12
2.
6
(0
.7
)
11
8.
8
(0
.5
)
D
ia
st
ol
ic
bl
oo
d
pr
es
su
re
(m
m
H
g)
73
.9
(0
.2
)
76
.4
(0
.4
)
71
.5
(0
.2
)
73
.8
(0
.3
)
75
.3
(0
.4
)
73
.0
(0
.4
)
H
D
L
ch
ol
es
te
ro
l
(m
g/
dl
)
50
.6
(0
.4
)
45
.7
(0
.5
)
55
.2
(0
.5
)
50
.2
(0
.5
)
54
.9
(0
.6
)
47
.9
(0
.5
)
Tr
ig
ly
ce
rid
es
(m
g/
dl
)
25
2.
5
(3
1.
0)
29
4.
8
(3
9.
4)
21
2.
6
(3
4.
9)
25
8.
7
(3
3.
2)
20
3.
5
(3
1.
1)
26
2.
8
(3
5.
7)
Pl
as
m
a
gl
uc
os
e
(m
g/
dl
)
99
.5
(0
.5
)
10
2.
6
(0
.6
)
96
.6
(0
.7
)
99
.1
(0
.5
)
10
1.
1
(1
.3
)
10
2.
4
(0
.8
)
Pe
rs
on
-y
ea
rs
of
fo
llo
w
-u
p
14
.3
(0
.2
)
14
.2
(0
.2
)
14
.3
(0
.2
)
14
.2
(0
.3
)
14
.2
(0
.2
)
14
.5
(0
.3
)
a
P
a
rt
ic
ip
a
n
ts
w
e
re
e
xc
lu
d
e
d
if
th
e
y
w
e
re
:
p
re
g
n
a
n
t
w
o
m
e
n
;
m
is
si
n
g
a
n
th
ro
p
o
m
e
tr
ic
,
la
b
o
ra
to
ry
,
o
r
b
lo
o
d
p
re
ss
u
re
m
e
a
su
re
m
e
n
ts
;
fa
st
in
g
le
ss
th
a
n
8
h
;
o
r
m
e
d
ic
a
l
h
is
to
ry
o
f
c
a
n
c
e
r
(a
ll
c
a
n
c
e
rs
e
xc
e
p
t
sk
in
c
a
n
c
e
r)
o
r
C
V
D
(c
o
ro
n
a
ry
h
e
a
rt
d
is
e
a
se
,
h
e
a
rt
a
tt
a
c
k,
o
r
st
ro
ke
).
b
S
m
o
ki
n
g
st
a
tu
s
d
e
fin
e
d
a
s:
c
u
rr
e
n
t
sm
o
ke
rs
(s
e
lf-
re
p
o
rt
e
d
c
u
rr
e
n
t
sm
o
ke
r)
,
fo
rm
e
r
sm
o
ke
r
(1
0
0
1
c
ig
a
re
tt
e
s
in
lif
e
tim
e
a
n
d
n
o
t
c
u
rr
e
n
t
sm
o
ke
r)
,
a
n
d
n
e
ve
r
sm
o
ke
r
(h
a
s
n
o
t
sm
o
ke
d
1
0
0
1
c
ig
a
re
tt
e
s
in
lif
e
tim
e
a
n
d
n
o
t
c
u
rr
e
n
t
sm
o
ke
r)
.
c
A
lc
o
h
o
l
c
o
n
su
m
p
tio
n
d
e
fin
e
d
a
s
fir
st
h
a
vi
n
g
a
t
le
a
st
1
2
a
lc
o
h
o
l
d
rin
ks
in
th
e
p
a
st
1
2
m
o
n
th
s
to
d
is
tin
g
u
is
h
b
e
tw
e
e
n
d
rin
ke
rs
a
n
d
n
o
n
d
rin
ke
rs
.
A
m
o
n
g
th
o
se
w
h
o
h
a
d
a
t
le
a
st
1
2
a
lc
o
h
o
lic
d
rin
ks
,
a
n
a
ve
ra
g
e
n
u
m
b
e
r
o
f
d
rin
ks
p
e
r
w
e
e
k
w
a
s
c
a
lc
u
la
te
d
a
n
d
c
a
te
g
o
riz
e
d
a
s
<
3
o
r
3
d
rin
ks
p
e
r
w
e
e
k.
d
P
h
ys
ic
a
l
a
c
tiv
ity
w
a
s
c
a
te
g
o
riz
e
d
a
s
a
c
tiv
e
o
r
in
a
c
tiv
e
.
A
c
tiv
e
w
a
s
d
e
fin
e
d
a
s
a
t
le
a
st
3
0
m
in
o
f:
m
o
d
e
ra
te
p
h
ys
ic
a
l
a
c
tiv
ity
a
t
le
a
st
fiv
e
tim
e
s
p
e
r
w
e
e
k
o
r
vi
g
o
ro
u
s
p
h
ys
ic
a
l
a
c
tiv
ity
a
t
le
a
st
th
re
e
tim
e
s
p
e
r
w
e
e
k.
e
S
e
lf-
re
p
o
rt
e
d
m
e
d
ic
a
tio
n
u
se
.
f M
e
ta
b
o
lic
sy
n
d
ro
m
e
N
H
L
B
I
d
e
fin
iti
o
n
is
d
e
fin
e
d
a
s
h
a
vi
n
g
th
re
e
o
r
m
o
re
o
f
th
e
fo
llo
w
in
g
c
h
a
ra
c
te
ris
tic
s:
(1
)
sy
st
o
lic
b
lo
o
d
p
re
ss
u
re
1
3
0
m
m
H
g
o
r
d
ia
st
o
lic
b
lo
o
d
p
re
ss
u
re
8
5
m
m
H
g
,
(2
)
fa
st
in
g
g
lu
c
o
se
1
0
0
m
g
/
d
l,
(3
)
tr
ig
ly
c
e
rid
e
s
1
5
0
m
g
/d
l,
(4
)
H
D
L
c
h
o
le
st
e
ro
l
<
4
0
m
g
/d
l
fo
r
m
e
n
o
r
<
5
0
m
g
/d
l
fo
r
w
o
m
e
n
,
o
r
(5
)
w
a
is
t
c
irc
u
m
fe
re
n
c
e
1
0
2
c
m
fo
r
m
e
n
o
r
8
8
c
m
fo
r
w
o
m
e
n
.
C
I,
c
o
n
fid
e
n
c
e
in
te
rv
a
l;
S
E
,
st
a
n
d
a
rd
e
rr
o
r.
Obesity Metabolic Syndrome and CVD Mortality Mercado et al.
1914 Obesity | VOLUME 23 | NUMBER 9 | SEPTEMBER 2015 www.obesityjournal.org
The greatest variation in factor loadings across race/ethnic groups in
men was between systolic (ranging from 0.34 to 0.43) and diastolic
(ranging from 0.25 to 0.57) blood pressures. In women, standardized
factor loadings for metabolic components varied more across race/
ethnic groups compared with men with the largest range observed
for waist circumference (0.58-0.80). Standardized factor loadings
estimated without correlated errors for SBP and DBP as well as
HDL and TG are shown on Supporting Information Figure S1. Since
estimated covariance between SBP and DBP as well as HDL and
TG were significantly different than zero (P value <0.05, and in
most cases P value <0.001), all further results only considered
MetS score derived from the path diagrams with specified correlated
error. Based on the SRMR and CD, all path diagrams had good fit.
The metabolic score derived from the structural equation modeling
was associated with CVD mortality for: non-Hispanic white women
(1.29, 1.01-1.64), non-Hispanic black women (2.03, 1.12-3.69), and
Mexican-American women (3.57, 2.21-5.76) (Table 3, unadjusted
estimates Supporting Information Table S3). In this study, the
harmonized defined MetS (yes/no) was not significantly associated
with CVD mortality in almost all of the gender and race/ethnic sub-
groups with the exception among non-Hispanic black women (2.69,
1.45-4.97). The number of abnormal metabolic components present
based on the harmonized definition was associated with CVD mor-
tality for: non-Hispanic white women (1.15, 1.04-1.27), non-
Hispanic black women (1.40, 1.10-1.77), and Mexican-American
women (1.32, 1.07-1.61). When comparing the models using the
metabolic score with those using harmonized MetS or the number of
abnormal metabolic components present, the models with the
metabolic score were a better fit based on the Akaike Information
Criterion and Bayesian Information Criterion. Using concordance
analysis, for the most part, the models with better predictability
TABLE 2 Cox proportional hazard ratio for CVD mortality associated with each standardizeda metabolic component
individually by gender—National Health and Nutrition Examination Survey III, United States
Men Women
N
No.
events HRb 95% CI P N
No.
events HRb 95% CI P
All 2721 220 3038 203
Waist circumference 1.02 (0.779-1.344) 0.870 1.14 (0.937-1.389) 0.189
Systolic blood pressure 1.50 (1.141-1.961) 0.004 1.44 (1.268-1.630) <0.0001
Diastolic blood pressure 1.48 (1.155-1.897) 0.002 1.24 (1.024-1.510) 0.028
HDL cholesterol 1.09 (0.827-1.435) 0.542 1.01 (0.765-1.334) 0.944
Triglycerides 1.15 (1.122-1.168) <0.0001 1.18 (0.951-1.454) 0.134
Plasma glucose 1.03 (0.796-1.326) 0.834 1.09 (0.872-1.358) 0.455
Non-Hispanic white 1126 122 1318 125
Waist circumference 1.06 (0.759-1.474) 0.740 1.10 (0.875-1.390) 0.406
Systolic blood pressure 1.51 (1.060-2.155) 0.023 1.43 (1.221-1.680) <0.0001
Diastolic blood pressure 1.51 (1.096-2.072) 0.012 1.23 (0.962-1.572) 0.099
HDL cholesterol 1.01 (0.728-1.414) 0.933 1.03 (0.743-1.428) 0.859
Triglycerides 1.16 (1.129-1.186) <0.0001 1.19 (0.938-1.510) 0.153
Plasma glucose 0.97 (0.656-1.443) 0.891 1.12 (0.892-1.418) 0.321
Non-Hispanic black 762 55 902 54
Waist circumference 0.88 (0.601-1.299) 0.529 1.29 (0.919-1.803) 0.141
Systolic blood pressure 1.58 (1.166-2.131) 0.003 1.44 (1.177-1.753) 0.0004
Diastolic blood pressure 1.53 (1.212-1.930) 0.0004 1.26 (0.951-1.658) 0.108
HDL cholesterol 1.43 (1.137-1.786) 0.002 0.90 (0.634-1.288) 0.575
Triglycerides 0.73 (0.413-1.280) 0.270 1.46 (0.927-2.290) 0.103
Plasma glucose 1.11 (0.938-1.306) 0.228 0.92 (0.701-1.195) 0.516
Mexican-American 833 43 818 24
Waist circumference 1.01 (0.535-1.906) 0.975 1.36 (0.807-2.282) 0.249
Systolic blood pressure 1.61 (0.901-2.859) 0.108 1.97 (1.203-3.228) 0.007
Diastolic blood pressure 1.13 (0.739-1.716) 0.581 1.67 (0.799-3.494) 0.173
HDL cholesterol 0.86 (0.391-1.888) 0.706 0.87 (0.569-1.329) 0.519
Triglycerides 1.32 (0.907-1.913) 0.148 1.15 (0.763-1.726) 0.508
Plasma glucose 1.15 (0.793-1.665) 0.462 1.68 (1.404-2.014) <0.0001
Each hazard ratio is a model.
aAll metabolic components were standardized to the normal distribution (mean5 0 and standard deviation51) for the purpose of coefficient comparison across models.
bModels adjusted for age, smoking status, education, physical activity, alcohol consumption, and medication use for diabetes, hypertension, or high cholesterol.
HR, hazard ratio; CI, confidence interval.
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were those with the metabolic score based on the Harrell’s C
coefficient and G€onen and Heller’s K coefficient (Supporting Infor-
mation Table S4). However, having all metabolic components as
continuous variables in the model had the best fit.
Discussion
SEM to examine the associations between MetS and cardiovascular
mortality has been sparsely utilized, yet it offers some advantages in
assessing risk including considering actual values for each MetS
component, their collective association with cardiovascular risk, and
allowing the collective influence of MetS components to vary within
subgroups of race/ethnicity and gender. MetS conceptually has been
an information reduction approach in identifying those individuals at
greater risk for CVD mortality instead of considering all components
as predictors which resulted in the best fit and predictability model
(Supporting Information Table S4). However, among the three forms
of defining metabolic syndrome, the metabolic score estimated from
Figure 1 Metabolic score path diagrams with standardized factor loadings for each gender-race subgroup among US adults—National Health and Nutrition Exami-
nation Survey III, 1988–2006. WC, waist circumference; SBP, systolic blood pressure; DBP, diastolic blood pressure; HDL, high-density lipoprotein; TG, triglycer-
ides; FG, fasting glucose.
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SEM was a slightly better predictor for CVD mortality compared
with harmonized MetS or the number of metabolic components pres-
ent in this study of a representative sample of US adults.
Of all the metabolic components, systolic and diastolic blood pres-
sure measures were repeatedly independently associated with CVD
mortality across gender and race/ethnicity subgroups. Even though
systolic blood pressure and diastolic blood pressure were associated
with CVD mortality in this study, it is an association previously
documented in other studies (16-18). Although it has been previ-
ously recognized that waist circumference (19-21), triglycerides
(22), and fasting glucose (23) are independently associated with
CVD risk; these findings were not consistent in this study. There
were no significant associations observed with waist circumference
and CVD mortality. Several significant linear associations with
CVD mortality were observed within selected groups, including:
fasting glucose among Mexican-American women, triglycerides
among non-Hispanic white men, HDL cholesterol among non-
Hispanic black men, and blood pressure among all groups except
Mexican-American men. Dichotomizing these variables, as what is
done in the harmonized MetS, may lose the effectiveness of quanti-
fying CVD risk.
Many studies have found MetS to be associated with CVD events
and/or mortality (13,24-32). Even though this association was not
observed in this study, some reasons for the discrepancy could be
due to the MetS definition used and the study population. Before the
release of the harmonized definition in 2009, all MetS studies varied
on the components and cut points used to define MetS relying on
definitions from the World Health Organization, European Group
for the Study of Insulin Resistance, National Cholesterol Education
Program, American College of Endocrinology, or International Dia-
betes Federation. Although systematic reviews and meta-analyses on
this topic have been consistent showing a positive association
between MetS and CVD (13,24-26,28,32), the findings between
studies were variable and the harmonized definition used in this
study has been reported to attenuate results more so than the other
definitions (11,12,27). Furthermore, some studies would substitute
certain measures for others based on the data collected, such as
using body mass index as opposed to waist circumference. In addi-
tion, the majority of the studies that investigated the association
between MetS and CVD events or mortality were conducted among
populations outside of the US. The few studies from the US were
not very diverse or did not report results within gender or race/eth-
nic subgroups.
A major weakness of all the MetS definitions is that quantifying
CVD risk is limited to yes/no and differentiation of CVD risk
between combinations of components is ignored. Components may
not weigh equally towards CVD risk and different clusters of com-
ponents may increase CVD risk more so than others (27,31). In a
study by Huang et al. (27), the cluster of high blood pressure, HDL,
and WC appeared to have the highest risk for CVD mortality of all
combinations, even compared with having all metabolic components
present. They also observed that having high blood pressure, HDL,
WC, and FG decreased the risk by half compared with if FG was
not in the cluster. The underlying etiology of how the components
interact to increase CVD risk is unknown. We do not fully under-
stand the relationship all metabolic components have in relation to
CVD risk and two-way, three-way, four-way, or a five-way interac-
tion between metabolic components may be present. As a result,
using harmonized MetS or treating metabolic components individu-
ally may not be the most effective way to assess or address CVD
risk, especially among certain subgroups or populations.
Previous studies using SEM to assess MetS with CVD risk have
found positive associations with atherosclerosis, coronary artery cal-
cification, diabetes, carotid intima media thickness, and CVD mor-
tality (33-37). Although gender and race/ethnicity subgroup differen-
ces in MetS using SEM has been noted (34,38,39); the previous
studies either did not consider these differences, examined different
path diagrams, or had study populations from other countries com-
pared with this study. However, across all studies, the consensus
was that assessing MetS using SEM was more effective in estimat-
ing CVD risk than MetS (yes/no).
There are a few limitations in this study. First, the follow-up time is
based on linkage to death certificates from the National Death Index
TABLE 3 Cox proportional hazard ratioa for the association between metabolic syndrome (score and traditional definition) and
CVD mortality stratified by gender and race—National Health and Nutrition Examination Survey III, United States
N No. events
Metabolic scoreb Metabolic syndrome
No. metabolic
components
HR 95% CI P HR 95% CI P HR 95% CI P
Men 2721 220 1.28 (0.961-1.701) 0.092 1.08 (0.780-1.491) 0.648 1.02 (0.884-1.181) 0.770
Non-Hispanic white 1126 122 1.41 (0.978-2.023) 0.066 1.13 (0.758-1.674) 0.555 1.02 (0.856-1.226) 0.793
Non-Hispanic black 762 55 0.90 (0.617-1.323) 0.602 0.89 (0.491-1.616) 0.704 0.98 (0.777-1.243) 0.885
Mexican-American 833 43 1.36 (0.726-2.544) 0.337 0.88 (0.372-2.067) 0.763 1.04 (0.725-1.485) 0.842
Women 3038 203 1.34 (1.059-1.683) 0.015 1.27 (0.899-1.806) 0.174 1.16 (1.056-1.276) 0.002
Non-Hispanic white 1318 125 1.29 (1.009-1.644) 0.042 1.16 (0.782-1.708) 0.467 1.15 (1.036-1.267) 0.008
Non-Hispanic black 902 54 2.03 (1.116-3.689) 0.020 2.69 (1.453-4.969) 0.002 1.40 (1.103-1.766) 0.006
Mexican-American 818 24 3.57 (2.209-5.759) <0.0001 1.99 (0.691-5.705) 0.203 1.32 (1.072-1.613) 0.009
aModels adjusted for age, smoking status, education, physical activity, alcohol consumption, and medication use for diabetes, hypertension, or high cholesterol.
bMetabolic score used in the models was derived specifically for each individual subgroup.
HR, hazard ratio; CI, confidence interval.
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and it is possible that some deaths might have been missed. Second,
we were unable to capture CVD events; we only had data on CVD
mortality which limits our ability to assess the association with
MetS and overall CVD risk. Third, the structural equation model
proposed may not represent the true underlying etiology, especially
if there are interactions between components. We considered each
metabolic component acting independently although simultaneously
in contributing to the metabolic score, but we may need to consider
how the values of some components may affect the values of
another to further increase CVD risk. Additionally, the structural
equation model assumed a reflective approach implying that changes
in the latent variable, MetS score, affect each component as opposed
to the counterfactual formative approach inferring that changes in
the components affect the MetS score. Potential mis-specification of
the model approach can be problematic in determining which com-
ponents load on a factor when performing traditional factor analysis
(40). However, in our study we did not conduct any exploratory
analysis to determine which variables to include as components of
the MetS score but tested a pre-specified structural equation model
based on predetermined risk factors and therefore potential mis-
specification of the model would not affect our results. Fourth,
although we were able to link to mortality data, all measured data
were of cross-sectional design and only obtained at baseline. There-
fore, changes may have occurred during follow-up time that changed
CVD risk; such as initiation of medication use, diagnosis, or medical
procedures; could not be accounted for in this study. Fifth, many
statistical tests were performed and some significant results may
have occurred due to chance. Finally, significant differences in the
SEM analyses may have been a function of large sample sizes.
Future studies are needed to understand the etiology of metabolic
components and how they may interact or relate to CVD risk.
Although studies have shown CVD risk differences by gender and
by race, most studies do not show results within race-gender subca-
tegories and there is a need for more research in this area. Another
research focus needed is investigations within subcategories of CVD
due to the heterogeneity of this category (e.g., stroke, heart attack,
or arrhythmia). Risk assessment using harmonized MetS may not
capture or distinguish risk severity for CVD mortality. Although it
has been previously stated that treatment for MetS is no different
than the treatment of each component (8) and it may be the best
current approach, treating individual risk factors independently may
not be the most effective treatment method due to possible interac-
tions between components which may require consideration of the
relationship these factors have with each other. Other than diet and
physical activity which may affect all components, we recognize
that at this time treating each component individually and focusing
on prevention are the best practices available until more is learned
and the knowledge gap is narrowed. In this study, SEM to assess
CVD mortality risk provided additional information than harmonized
MetS or the number of MetS components present in that predictions
became significant when using the metabolic score. Although the
metabolic score driven from SEM has the potential to accurately
estimate CVD risk tailored for different subgroups and therefore
have positive clinical and public health implications, at this time
more knowledge is needed on the etiology between metabolic com-
ponents and CVD risk to establish the true path diagram and may
be the reason that the models with all the components present pre-
dicted CVD mortality better than any of the MetS approaches. Even
though calculations of the metabolic score using SEM is complex
posing impractical risk assessment ability in the clinical setting, the
future of electronic medical records may be able to take the actual
metabolic component values and estimate more accurate CVD risk
tailored for certain subgroups.O
VC 2015 The Obesity Society
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Table S1. Unadjusted Cox Proportional Hazard Ratio for Cardiovascular Disease Mortality associated with each STANDARDIZEDa 
metabolic component by gender-  National Health and Nutrition Examination Survey III, United States 
 Men  Women 
 N 
# of 
events 
HRb 95% CI P-value  N 
# of 
events 
HRb 95% CI P-value 
All 2721 220     3038 203    
     Waist circumference    1.12  (0.852, 1.473) 0.418    1.23  (1.015, 1.499) 0.035 
     Systolic blood pressure    1.53  (1.142, 2.045) 0.004    1.41  (1.226, 1.621) 0.000 
     Diastolic blood pressure    1.41  (1.117, 1.783) 0.004    1.28  (1.062, 1.533) 0.009 
     HDL cholesterol   0.95  (0.689, 1.315) 0.765    1.02  (0.788, 1.327) 0.867 
     Triglycerides   1.12  (1.104, 1.133) 0.000    1.21  (1.000, 1.465) 0.050 
     Plasma glucose   1.16  (0.986, 1.370) 0.074    1.12  (0.978, 1.281) 0.101 
Non-Hispanic white 1126 122     1318 125    
     Waist circumference    1.22  (0.894, 1.672) 0.208    1.19  (0.945, 1.496) 0.140 
     Systolic blood pressure    1.53  (1.049, 2.237) 0.027    1.35  (1.150, 1.592) 0.000 
     Diastolic blood pressure    1.41  (1.059, 1.876) 0.019    1.25  (1.014, 1.535) 0.037 
     HDL cholesterol   0.81  (0.542, 1.196) 0.283    1.04  (0.776, 1.398) 0.786 
     Triglycerides   1.13  (1.109, 1.142) 0.000    1.23  (0.998, 1.524) 0.053 
     Plasma glucose   1.15  (0.931, 1.421) 0.193    1.13  (0.959, 1.325) 0.147 
Non-Hispanic black 762 55     902 54    
     Waist circumference    0.89  (0.620, 1.265) 0.504    1.39  (1.012, 1.919) 0.042 
     Systolic blood pressure    1.52  (1.127, 2.047) 0.006    1.52  (1.265, 1.817) 0.000 
     Diastolic blood pressure    1.53  (1.212, 1.924) 0.000    1.29  (1.022, 1.638) 0.032 
     HDL cholesterol   1.31  (1.040, 1.657) 0.022    0.92  (0.669, 1.271) 0.620 
     Triglycerides   0.80  (0.453, 1.400) 0.429    1.41  (0.909, 2.179) 0.125 
     Plasma glucose   1.20  (1.037, 1.392) 0.015    1.02  (0.887, 1.180) 0.751 
Mexican-American 833 43     818 24    
     Waist circumference    0.81  (0.425, 1.524) 0.505    1.52  (0.978, 2.351) 0.063 
     Systolic blood pressure    1.39  (0.830, 2.324) 0.211    2.22  (1.343, 3.684) 0.002 
     Diastolic blood pressure    0.97  (0.693, 1.344) 0.835    1.51  (0.667, 3.415) 0.323 
     HDL cholesterol   0.81  (0.353, 1.850) 0.614    0.74  (0.489, 1.111) 0.145 
     Triglycerides   1.32  (0.924, 1.895) 0.127    1.16  (0.836, 1.604) 0.378 
     Plasma glucose   1.09  (0.793, 1.501) 0.594    1.38  (1.129, 1.678) 0.002 
Abbreviations:  HR, hazard ratio; CI, confidence interval 
a All metabolic components were standardized to the normal distribution for the purpose of coefficient comparison across models.  
b Models adjusted for age. 
 
 
 
Table S2.  P-values for testing differences in structural equation models by gender and race  
              Men   Women 
 Gender  Race  Race  Race 
  
Score 
Testa 
Wald 
Testb   
Score 
Testa 
Wald 
Testb   
Score 
Testa 
Wald 
Testb   
Score 
Testa 
Wald 
Testb 
Waist circumference <0.0001 <0.0001  0.015 <0.0001  0.658 0.0016  0.0001 <0.0001 
Systolic blood pressure <0.0001 <0.0001  0.012 <0.0001  0.338 0.0010  0.110 0.0001 
Diastolic blood pressure 0.732 0.040  <0.0001 <0.0001  <0.0001 <0.0001  0.006 <0.0001 
HDL cholesterol 0.018 <0.0001  <0.0001 <0.0001  <0.0001 <0.0001  0.003 <0.0001 
Triglycerides <0.0001 <0.0001  0.001 <0.0001  0.415 <0.0001  <0.0001 <0.0001 
Fasting glucose 0.043 0.012   <0.0001 <0.0001   0.394 <0.0001   <0.0001 <0.0001 
NOTE:  Testing differences in structural equation models could not be performed in the survey setting.  Therefore, these results do not 
consider sampling design or weights. 
a Score test reported for testing difference in factor loadings across groups.  The null hypothesis is that the factor loadings are equal. 
b Wald test reported for testing difference in the variance for parameters across groups.  The null hypothesis is that the variance is equal across 
groups.  
 
 
 
 
 
 
 
 
 
 
 
Table S3.  Unadjusted Cox proportional hazard ratioa for the association between Metabolic syndrome (score and traditional definition) and CVD mortality 
stratified by gender and race – National Health and Nutrition Examination Survey III, United States 
  
N # of events 
Metabolic Scoreb   Metabolic Syndrome   # of Metabolic Components 
  HR 95% CI P-value   HR 95% CI P-value   HR 95% CI P-value 
Men 2721 220 1.43  (1.140, 1.801) 0.002  1.35  (0.979, 1.859) 0.067  1.13  (0.986, 1.298) 0.079 
     Non-Hispanic white 1126 122 1.61  (1.254, 2.064) 0.0002  1.50  (1.033, 2.169) 0.033  1.16  (0.994, 1.359) 0.060 
     Non-Hispanic black 762 55 0.97  (0.672, 1.384) 0.845  0.93  (0.517, 1.668) 0.804  1.06  (0.858, 1.316) 0.578 
     Mexican-American 833 43 1.06  (0.602, 1.870) 0.839  0.75  (0.313, 1.782) 0.511  0.98  (0.712, 1.336) 0.876 
              
Women 3038 203 1.40  (1.143, 1.714) 0.001  1.46  (1.067, 1.988) 0.018  1.20  (1.103, 1.314) <0.0001 
     Non-Hispanic white 1318 125 1.33  (1.081, 1.644) 0.007  1.34  (0.963, 1.873) 0.082  1.19  (1.086, 1.299) 0.0002 
     Non-Hispanic black 902 54 2.03  (1.304, 3.163) 0.002  2.51  (1.467, 4.300) 0.001  1.37  (1.141, 1.646) 0.001 
     Mexican-American 818 24 2.44  (1.684, 3.523) <0.0001  2.33  (0.733, 7.383) 0.152  1.34  (1.085, 1.658) 0.007 
Abbreviations:  HR, hazard ratio; CI, confidence interval 
a Models adjusted for age.  
b Metabolic score used in the models were derived specifically for each individual subgroup. 
 
 
 
 
 
 
 
 
 
 
 
 
Table S4.  Goodness-of-fit and Predictability Results for the Comparison Between Models Using Metabolic Score, Metabolic 
Syndrome, or Number of Metabolic Components by Gender-Race Subgroups 
 Metabolic Score  Metabolic Syndrome Prevalence  
 AIC BIC 
C 
statistic 
K 
statistic 
R 
square 
 AIC BIC 
C 
statistic 
K 
statistic 
R 
square 
Men            
Non-Hispanic white 578.58 623.81 0.881 0.848 0.561  581.24 626.48 0.881 0.847 0.553 
Non-Hispanic black 442.48 484.21 0.865 0.799 0.692  442.71 484.43 0.864 0.802 0.691 
Mexican-American 253.32 295.85 0.875 0.806 0.558  253.44 295.97 0.872 0.800 0.557 
Women            
Non-Hispanic white 723.51 770.16 0.915 0.868 0.716  725.38 772.03 0.915 0.866 0.712 
Non-Hispanic black 465.18 508.42 0.912 0.819 0.898  463.83 507.07 0.912 0.809 0.900 
Mexican-American 140.55 178.20 0.922 0.842 0.800  151.40 193.76 0.916 0.829 0.720 
 # of Metabolic Components  All components in model  
 AIC BIC 
C 
statistic 
K 
statistic 
R 
square 
 AIC BIC 
C 
statistic 
K 
statistic 
R 
square 
Men            
Non-Hispanic white 581.33 626.57 0.881 0.847 0.553  366.74 433.17 0.888 0.851 0.576 
Non-Hispanic black 442.80 484.52 0.864 0.802 0.690  355.26 417.09 0.899 0.815 0.805 
Mexican-American 253.63 296.16 0.872 0.799 0.556  195.37 257.12 0.881 0.795 0.614 
Women            
Non-Hispanic white 723.74 770.39 0.916 0.868 0.716  478.31 547.49 0.928 0.873 0.764 
Non-Hispanic black 466.69 509.93 0.908 0.810 0.895  315.56 379.19 0.921 0.817 0.920 
Mexican-American 150.97 193.33 0.917 0.829 0.725  93.38 154.54 0.925 0.852 0.883 
AIC, Akaike Information Criterion; BIC, Bayesian Information Criterion; C statistic, Harrell’s C-coefficient; K statistic, Gönen and 
Heller’s K-coefficient; R square, Royston’s R-square 
For both AIC and BIC, smaller number is a better fit. 
For R-square, C- and K- statistics, the larger number is a better predictor. 
All components in the model include: waist circumference, systolic blood pressure, diastolic blood pressure, HDL cholesterol, 
triglycerides, and fasting glucose as proxy for metabolic syndrome along with  
 
 
 
 Supplemental Figure 1. Metabolic Score Path Diagrams with Standardized Factor Loadings for 
Each Gender-Race Subgroup without Correlated Errors 
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